A drug formulation can be perfect. The clinical data solid. The regulatory filing complete. And still, the product reaches the market years after the window was viable. That was the operational reality at Dr. Reddy's Integrated Product Development Organisation (IPDO) before 2009. Their average cycle time from formulation to regulatory filing: 915 days, nearly two and a half years.
Why smart people produce slow projects
The problem was not the scientists, the equipment, or the regulatory framework. It was the structure of the project management system itself, and three dysfunctions baked into it.
First, Student Syndrome: when people have a task estimate with safety built in, they start late. The safety is consumed before work begins. A task with five days of safety behaves like a task with zero. Second, Parkinson's Law: work expands to fill available time. Early finishes disappear into polishing, rechecking, or waiting for the scheduled handoff. Third, dependency accumulation: at every integration point, only delays cascade forward; early finishes don't compensate. In a pharma R&D environment with dozens of interdependent tasks across formulation, stability, analytical, and regulatory work, these three dynamics compound relentlessly.
What Critical Chain Project Management changed
The CCPM implementation at Dr. Reddy's IPDO, completed in December 2009, changed four things.
Task estimates were cut to the 50th percentile. No individual contingency. The safety removed from each task was aggregated into a project buffer at the end of the critical chain, statistically more efficient than distributing safety across 40 individual tasks.
The Critical Chain was calculated, not just the Critical Path. The Critical Path ignores resource conflicts. A schedule that assigns the same analytical scientist to two parallel tasks simultaneously is logically valid and physically impossible. CCPM resource-levels the network first, then calculates the longest chain. In pharma R&D, where senior scientists and regulatory writers are chronically overloaded, this distinction determines whether the schedule is executable.
Execution was managed by buffer health, not milestone dates. A fever chart tracked buffer consumption against critical chain completion. A project 80% through the chain that has consumed 40% of its buffer is performing well. One that is 80% through and has consumed 80% of its buffer needs escalation. Objective, non-political, visible to everyone.
WIP was controlled at the portfolio level. New projects were not released into execution until the pipeline could absorb them. This feels counterintuitive, it seems like holding back projects slows the organization. In practice, limiting simultaneous active projects means each one gets more resource attention, moves faster, and finishes sooner, including the ones that were held back.
The behavioral change that made it work
The technical changes mattered less than one behavioral change: individual task performance was no longer measured against task estimates. This single decision removed the incentive to inflate estimates and the incentive to consume all available time. When a scientist finished two days early, the next task started immediately, not on its scheduled start date. The relay-runner handoff replaced the calendar-controlled handoff.
This change cannot be authorized by a project manager. It requires senior leadership to explicitly endorse a different measurement system. Without that endorsement, scientists will protect themselves by re-inflating estimates to the 85th percentile, and the project buffers will be consumed before the first milestone.
The results
Dr. Reddy's Laboratories reduced their formulation-to-filing cycle time from 915 days to 563 days, a 48% reduction. Filing throughput increased by 45%. Launch throughput increased by 51%. Due date performance improved by 30 to 80 percentage points depending on project type.
A 48% reduction in pharma R&D cycle time means products reach market 16 months earlier, 16 months of patent-protected revenue on each product. For a pipeline with $500M in development-stage products, the financial return is measured in hundreds of millions, not consulting fees. It also makes Dr. Reddy's a more reliable partner for licensing deals, co-development agreements, and supply commitments. Operational predictability is a commercial argument, not just an operational one.
The competitive window is real: implementing CCPM requires 12 to 18 months of behavioral change. A competitor who sees these results cannot replicate them next quarter.
What most organizations copy wrong
Organizations implementing CCPM after seeing results like Dr. Reddy's typically get the scheduling right and get the behavioral changes wrong. They cut task estimates but continue measuring people against them. The scientist's estimate immediately inflates back to the 85th percentile. The tool is in place. The measurement system destroys the benefit.
The second mistake: adding project buffers to a portfolio with 40 simultaneous active projects will improve scheduling clarity but will not reduce cycle time. The constraint is shared resources, senior scientists, analytical labs, regulatory writers. Until WIP is limited to match their capacity, buffers are consumed before execution begins.
One action you can take this week
Take your three most-delayed active projects. Ask the project manager one question: "What is currently blocking progress?" In most cases, the answer is a shared resource working on three things simultaneously. That is your WIP control problem. The CCPM implementation can follow, but stopping the multi-tasking hemorrhage at the constraint is the first move, and you can make it this week.
Upcoming TOC events
- June 23 (Online, Free), Stop Optimizing Projects. Start Optimizing the System., TOCICO webinar on why local project improvements don't translate to organizational gains in delivery and throughput.
- June 30 (Online, Free), Introduction to TOC: Critical Chain Project Management (CCPM), TOCICO's practical introduction to CCPM: cut project duration by 25, 50% without adding resources.
- July 21, 22 (Kyoto, Japan, $400), Goldratt Global Annual Conference, The premier annual TOC gathering. Speakers include the CEO of Hertz and executives from Delta Air Lines and Vale.